Say you’re a struggling early-stage biotech company in a hot area, there are few more desirable things to have happen than for the NY Times to write favorably about you in a Sunday NY Times piece — one that also calls your area, obesity drugs, hot.
Well, here is how to screw up the favorable mention: Forget to pay to have your domain name renewed. That is apparently what Nastech Pharmaceuticals did, and that is why when you go to the company’s website you currently get:
This domain name expired on 03/28/2005 and is pending renewal or deletion.
Gosh, I hate when that happens. More seriously, while the kids at Yahoo Finance are trying to put a brave face on their favorite stock ticker’s screw-up, you have to wonder at people who don’t pay attention to such details. A biotech company that can’t get the arcana right is, let’s just say, an unsettling prospect.
Related posts: